Is Novocure Ltd (NVCR) overvalued? · rev $605.2M
Novocure Ltd (NVCR) is a medical devices company listed on US.
This page asks whether Novocure Ltd (NVCR) looks expensive on cached numbers — not a short thesis.
Latest reported NVCR revenue for 2024-12-31 was $605.2M. Net income was -$168.6M. Revenue was up 18.8% from 2023-12-31 to 2024-12-31. NVCR currently screens at market cap $1.99B.
NVCR currently screens at market cap $1.99B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NVCR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NVCR stock page for the full model, not this heading.
Not investment advice.